Boothwyn Pharmacy
Boothwyn Pharmacy is a 503A compounding pharmacy based in Kennett Square, PA. A government record names semaglutide and tirzepatide at Boothwyn Pharmacy; the newest is an FDA warning letter dated January 16, 2026. It fills prescriptions; it doesn’t write them, so you can’t get a GLP-1 from Boothwyn Pharmacy without a prescription from a licensed clinician.12
How to get a GLP‑1 filled by Boothwyn PharmacyChecked November 20, 2026 against FDA, CMS and state board records. Every fact links to its source.
Boothwyn Pharmacy at a glance
How to get a GLP‑1 filled by Boothwyn Pharmacy
To get a GLP‑1 from Boothwyn Pharmacy, you first need a prescription: it fills prescriptions; it doesn’t write them or sell without one. An online program takes you through the steps: you fill in a health questionnaire, a licensed clinician reviews it, and if they prescribe, the program’s pharmacy ships the medication to you.
2 programs we review name Boothwyn Pharmacy among its pharmacies; they’re listed below. These are the three programs ranked highest on our score.
- 1Health questionnaire, online
- 2A licensed clinician decides
- 3The pharmacy ships to you
We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money
Prefer your own clinician? You’re free to: ask them to send your prescription to Boothwyn Pharmacy or another licensed pharmacy.
See every program we rankWhat ties Boothwyn Pharmacy to GLP‑1s
- Its own siteNovember 18, 2026 · semaglutide and tirzepatideLists a GLP-1 product on its own site3
“Boothwyn Pharmacy compounds semaglutide only on a prescription basis, preparing each medication for the individual patient.”
- FDA warning letterJanuary 16, 2026 · semaglutide and tirzepatideFDA warning letter WL # 717525 to Boothwyn Pharmacy LLC6
“Accordingly, your Semaglutide 2.5mg/mL Injection and Tirzepatide 10mg/mL Injection are adulterated under section 501(c) of the FDCA.”
- FDA recallJuly 9, 2025 · semaglutideClass II recall D-0608-2025: Subpotent Drug7
“Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy”
- FDA recallJuly 9, 2025 · semaglutideClass II recall D-0606-2025: Subpotent Drug8
“Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy”
- FDA recallJuly 9, 2025 · semaglutideClass II recall D-0609-2025: Subpotent Drug9
“Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy”
- FDA inspection report (Form 483)June 9, 2025 · semaglutide and tirzepatideFDA Form 483 inspectional observations, Boothwyn Pharmacy LLC, issued 2025-06-0910
“SEMAGLUTIDE 2.5 MG/ML (2ML) INJ”
Boothwyn Pharmacy’s FDA record
| Date | What the FDA did |
|---|---|
| January 16, 2026 | Warning Letter Issued 01/16/20266 |
| June 9, 2025 | 483 Issued 06/09/202511 |
| May 13, 2024 | Regulatory Meeting Held 05/13/2024 |
| September 12, 2023 | Amended 483 Issued 9/12/202312 |
| September 8, 2021 | 483 Issued 09/08/202113 |
Telehealth programs that use Boothwyn Pharmacy
What a compounded GLP‑1 is, and what it isn’t
The bigger question with any compounded program is the drug itself. Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.2021 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.1914
Boothwyn Pharmacy: questions
- 1.Boothwyn Pharmacy: what it says it isboothwyn.comretrieved 2026-11-20↩“led to the opening of a dedicated 503A compounding site in Kennett Square, Pennsylvania, in 2017”
- 2.NPI Registry: BOOTHWYN PHARMACY LLC (NPI 1861561714)Centers for Medicare & Medicaid Servicesretrieved 2026-11-20↩
- 3.Lists a GLP-1 product on its own siteBoothwyn Pharmacyretrieved 2026-11-18↩“Boothwyn Pharmacy compounds semaglutide only on a prescription basis, preparing each medication for the individual patient.”
- 4.Zevay, a GLP-1 telehealth program, names it among its pharmaciesZevayretrieved 2026-10-24↩“Boothwyn Pharmacy, 221 Gale Lane, Kennett Square, PA”
- 5.ShedRx, a GLP-1 telehealth program, names it among its pharmaciesShedRxretrieved 2026-10-16↩“Boothwyn Pharmacy, 221 Gale Lane, Kennett Square, PA”
- 6.FDA warning letter WL # 717525 to Boothwyn Pharmacy LLCFDAretrieved 2026-01-16↩“Accordingly, your Semaglutide 2.5mg/mL Injection and Tirzepatide 10mg/mL Injection are adulterated under section 501(c) of the FDCA.”
- 7.Class II recall D-0608-2025: Subpotent DrugU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-09↩“Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy”
- 8.Class II recall D-0606-2025: Subpotent DrugU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-09↩“Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy”
- 9.Class II recall D-0609-2025: Subpotent DrugU.S. Food and Drug Administration, Enforcement Report (openFDA)retrieved 2025-07-09↩“Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy”
- 10.FDA Form 483 inspectional observations, Boothwyn Pharmacy LLC, issued 2025-06-09FDAretrieved 2025-06-09↩“SEMAGLUTIDE 2.5 MG/ML (2ML) INJ”
- 11.FDA: 483 Issued 06/09/2025 (PDF - 2 MB)U.S. Food and Drug Administration↩
- 12.FDA: Amended 483 Issued 9/12/2023 (PDF - 931 KB)U.S. Food and Drug Administration↩
- 13.FDA: 483 Issued 09/08/2021 (PDF - 11 MB)U.S. Food and Drug Administration↩
- 14.Compounding inspections, recalls, and other actionsU.S. Food and Drug Administrationretrieved 2026-11-20↩
- 15.Pennsylvania license lookuppals.pa.gov↩
- 16.ACHC/PCAB: accreditation directoryorganization.achc.orgretrieved 2026-11-18↩
- 17.LegitScript: accreditation directorylegitscript.comretrieved 2026-11-18↩
- 18.Boothwyn Pharmacy: where it shipsboothwyn.comretrieved 2026-11-20↩“Select a state on the map, or choose one from the list, to see its licensure details.”
- 19.Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration↩
- 20.
- 21.
A pharmacy’s record can change after the day we read it: check its license with its state board before you fill a prescription. An FDA document is an allegation or an observation the FDA has published, not a court finding. This page is educational and is not medical advice.